Vertex Pharmaceuticals Incorporated
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Type 1 Diabetes
VX-264
PHASE1
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 17 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus |
Actual Study Start Date : | 2023-05-16 |
Estimated Primary Completion Date : | 2026-05 |
Estimated Study Completion Date : | 2026-05 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 65 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
UHealth Diabetes Research Institute
Miami, florida, United States, 33136
RECRUITING
University of Chicago
Chicago, Illinois, United States, 60637
RECRUITING
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
RECRUITING
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
RECRUITING
University of Pittsburgh Medical Center Montefiore
Pittsburgh, Pennsylvania, United States, 15213
RECRUITING
University of Wisconsin
Madison, Wisconsin, United States, 53792
RECRUITING
University of Alberta, Edmonton
Edmonton, Canada,
RECRUITING
Montreal Clinical Research Institute
Montreal, Canada,
RECRUITING
Toronto General Hospital (TGH)
Toronto, Canada,
RECRUITING
Vancouver General Hospital
Vancouver, Canada,
RECRUITING
Dresden Center for Islet Transplantation
Dresden, Germany,
RECRUITING
IRCCS San Raffaele Hospital
Milan, Italy,
RECRUITING
Leiden University
Leiden, Netherlands,
RECRUITING
Geneva University Hospitals
Geneva, Switzerland,
RECRUITING
Churchill Hospital
Headington, United Kingdom,
RECRUITING
Royal Victoria Infirmary
Newcastle Upon Tyne, United Kingdom,